Literature DB >> 16438155

Etiologies and treatment outcomes for out-patients with community-acquired pneumonia (CAP) at Srinagarind Hospital, Khon Kaen, Thailand.

Wipa Reechaipichitkul1, Viraphong Lulitanond, Kittisak Sawanyawisuth, Aroonlug Lulitanond, Panita Limpawattana.   

Abstract

Most patients with community-acquired pneumonia are treated as out-patients with empirical therapy, since initially the etiologic agent is unknown. We prospectively assessed the etiologies and treatment outcomes of pneumonia from February 2003 to 2004 at ambulatory clinics. Forty-four patients were included with a mean age of 49.2 (SD 18.2) years. The male to female ratio was 1:1.4. The incubation period was 6.9 (SD 4.4) days. Half of the patients were healthy. Asthma and COPD were common in patients with underlying diseases. The etiologic diagnosis was determined by a sputum culture and a serology test of paired serum samples. Hemo-culture produced no growth in any patients. Atypical pathogens and H. influenzae were the most common finding, each occurring in 31.8% of the patients followed by S. pneumoniae and H. parainfluenzae (27.3% each). Twenty-two patients were infected with multiple pathogens. C. pneumoniae was the most common co-infecting pathogen. Two of 12 S. pneumoniae isolates were penicillin resistant. Nine of 14 H. influenzae isolates were cotrimoxazole resistant and 8 of 14 were not sensitive to erythromycin. For H. parainfluenzae, 11 of 12 isolates were not sensitive to erythromycin, and 7 of 12 were not sensitive to cotrimoxazole. Oral antibiotics were prescribed as out-patient treatment. Forty patients (90.9%) improved, with symptoms-score improvement averaging 6.4 days. Four patients got worse and needed a change of antibiotics, the symptoms usually worsen within 3-5 days. We conclude that, antibiotics for CAP out-patients should cover atypical pathogens, H. influenzae, S. pneumoniae and H. parainfluenzae. If the clinical symptoms do not respond after 3-5 days of out-patient treatment, resistance or an unusual organism (eg B. pseudomallei) should be considered.

Entities:  

Mesh:

Year:  2005        PMID: 16438155

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  5 in total

1.  Are Pathogenic Leptospira Species Agents of Community-Acquired Pneumonia? Case Reports of Leptospirosis Presenting as Pneumonia.

Authors:  M Hussein Gasem; Helmia Farida; Ahmed Ahmed; Juliţte A Severin; Agus Suryanto; Bambang Isbandrio; Henri A Verbrugh; Rudy A Hartskeerl; Peterhans J van den Broek
Journal:  J Clin Microbiol       Date:  2015-10-28       Impact factor: 5.948

2.  Viruses and Gram-negative bacilli dominate the etiology of community-acquired pneumonia in Indonesia, a cohort study.

Authors:  Helmia Farida; M Hussein Gasem; Agus Suryanto; Monique Keuter; Nasirun Zulkarnain; Bambang Satoto; Annemiek A van der Eijk; R Djokomoeljanto; Hendro Wahyono; Henri A Verbrugh; Juliëtte A Severin; Peterhans J van den Broek
Journal:  Int J Infect Dis       Date:  2015-08-06       Impact factor: 3.623

Review 3.  The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review.

Authors:  Leon Peto; Behzad Nadjm; Peter Horby; Ta Thi Dieu Ngan; Rogier van Doorn; Nguyen Van Kinh; Heiman F L Wertheim
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-04-29       Impact factor: 2.184

4.  Blood Culture Bottle and Standard Culture Bottle Methods for Detection of Bacterial Pathogens in Parapneumonic Pleural Effusion.

Authors:  Surapan Charoentunyarak; Sarassawan Kananuraks; Jarin Chindaprasirt; Panita Limpawattana; Kittisak Sawanyawisuth
Journal:  Jundishapur J Microbiol       Date:  2015-10-29       Impact factor: 0.747

Review 5.  Etiologies and resistance profiles of bacterial community-acquired pneumonia in Cambodian and neighboring countries' health care settings: a systematic review (1995 to 2012).

Authors:  Sophie Goyet; Erika Vlieghe; Varun Kumar; Steven Newell; Catrin E Moore; Rachel Bousfield; Heng C Leang; Sokheng Chuop; Phe Thong; Blandine Rammaert; Sopheak Hem; Johan van Griensven; Agus Rachmat; Thomas Fassier; Kruy Lim; Arnaud Tarantola
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.